Fig. 11

a Box-and-whisker diagrams of VEGF-A serum levels in melanoma patients treated with BRAFi or BRAFi+MEKi. VEGF-A serum levels were measured in 26 melanoma patients (18 responders and 8 non-responders) before the start of therapy (T0), after two months of treatment (T2) and at disease progression (TP). The edges of each box represent the 75th and 25th percentile, respectively, and whiskers the maxima and minima. The horizontal bar within each box indicates the median. The outliers are denoted by dots. Data were analyzed by non-parametric Wilcoxon matched-pairs signed-rank test. ^*P<0.05 T0 non-responders vs T0 responders; ^§P<0.05 TP responders vs T2 responders; ^##P<0.01 T2 non-responders vs T2 responders. b Receiver operating characteristics curves (ROC) of VEGF-A levels in responder versus non-responder patients.